Hypertension in pregnancy: diagnosis and management

Healthcare products Regulatory Agency (MHRA) issued a drug safety update on ACE inhibitors and angiotensin II receptor antagonists: not for use in pregnancy, which states 'Use in women who are planning pregnancy should be avoided unless absolutely necessary, in which case the potential risks and benefits should be discussed'. 1.3.3 Stop antihypertensive treatment in women taking ACE inhibitors or ARBs if they become pregnant (preferably within 2 working days of notification of pregnancy) and offer alternatives. [2010] 1.3.4 Advise women who take thiazide or thiazide-like diuretics: • that there may be an increased risk of congenital abnormalities and neonatal complications if these drugs are taken during pregnancy • to discuss alternative antihypertensive treatment with the healthcare professional responsible for managing their hypertension, if they are planning pregnancy. [2010, amended 2019] 1.3.5 Advise women who take antihypertensive treatments other than ACE inhibitors, ARBs, thiazide or thiazide-like diuretics that the limited evidence available has not shown an increased risk of congenital malformation with such treatments. [2010, amended 2019] Treatment of chronic hypertension 1.3.6 Offer pregnant women with chronic hypertension advice on: • weight management • exercise • healthy eating • lowering the amount of salt in their diet. Provide this advice in
